Publikationen
Auswahl
Links zu ausgewählten Publikationen (open access):
American Journal of Psychiatry, Issue 1, 2025, special Edition „Psychedelics“
Sonderheft Suchtmedizin zu Psychedelika 6-2024
Spangemacher et al. 2024: Psilocybin als krankheitsmodifizierendes Arzneimittel
Aicher et al. 2024: Refining the claim of a paradigm shift
Jungwirth et al. 2024: Psilocybin depression empathy
Back et al. 2024: Psilocybin Depression Clinicians Covid
Villiger et al. 2024: Ethics How-to-make-psychedelic-assisted-therapy-safer
Herwig 2024: Einführung und klinische Studien zu Psychedelika
Herwig 2024: Geschichte der Anwendung von Psychedelika
Hartter et al. 2024: Einstellungen zur Einführung von Psychedelika
Schüle et al. 2024: Ketamin und Esketamin – Pharmakologie und Psychotherapie
Evens und Majic 2024: Postakute Effekte von klassischen Psychedelika
Herwig et al. 2024: Neurobiologische Wirkungen von Psychedelika
Daumann und Herwig 2024: Psychedelikaassistierte Psychotherapie – Risiken und Herausforderungen
Bechtold und Repantis: MDMA-gestützte Therapie
Passie 2024: Hanscarl Leuner und die Grundlagen der Psycholytischen Therapie
Langlitz et al. 2024: Neuroethics Psychedelic Therapy
Aicher et al. 2024: Psychedelika Psychotherapie Schweiz
Wolfson et al. 2024: Ketamin Psychotherapy
Barksdale et al. 2024: Neurobiology Psychedelics
Aaronson et al. 2023: Psilocybin Bipolar II
Nardou et al. 2023 (Nature): Psychedelic Social reward mouse model
Raison et al. 2023: Depression Psilocybin
Mitchell et al. 2023 (Nature Medicine): PTSD MDMA
Walsh et al. 2023: Depression LSD society use
Knatz et al. 2023 (Nature Medicine): Anorexia Psilocybin
Calder et al. 2023: Psychedelic safety
Volkow et al. 2023: Psychedelic opinion
Simonsson et al. 2023: Psilocybin depression risk
Evens et al. 2023: Psychedelic afterglow …
Buoso et al. 2023: Adverse effects of Ayahuasca …
Ryan et al. 2023: Experience of microdosing psychedelics …
Ponomarenko et al. 2023: Can psychedelics enhance group psychotherapy?
von Rotz et al. 2023: Single-dose psilocybin-assisted therapy in major depressive disorder …
Carhart-Harris 2023: Translational Challenges in Psychedelic Medicine
Avram et al. 2023 Thalamocortical connectivity LSD, MDMA, etc.
Bedford et al. 2023 Effect LSD brain connectivity
Murphy et al. 2022: Therapeutic Alliance and Rapport Modulate Responses to Psilocybin …
Mertens et al. 2022: EPIsoDE study design
Brody 2022: Psychedelic medicine (Nature outlook)
Irizarry et al. 2022: Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis
Gukasyan et al. 2022: Efficacy and safety of psilocybin-assisted treatment for major …
Oehen & Gasser 2022: Using a MDMA- and LSD-Group Therapy Model in Clinical …
Müller et al. 2022 Flashback LSD Psilocybin Healthy
Avram et al. 2022 Thalamocortical Dysconnectivity LSD, MDMA, etc.
Fusar-Poli & Borgwardt 2019: Albert Hofmann the Father of LSD
Nutt & Carhart-Harris 2020: Psychedelic Psychiatries brave new world
Reiff et al. 2020: Psychedelics and Psychedelic assisted Psychotherapy
Davis et al. 2020: Effects of Psilocybin-Assisted Therapy on Major Depressive …
Bogenschutz et al. 2022: Percentage of heavy drinking days following Psilocybin-…
Goodwin et al. 2022: Single-Dose Psilocybin for a Treatment-Resistant Episode …
Müller et al. 2020: Hallucinogens and Entactogens – establishing a new class of …
Holze et al. 2019: Distinct acute effects of LSD, MDMA and D-amphetamine
Daws et al. 2022: Increased global integration in the brain after psilocybin …
McCulloch et al. 2022: Psychedelic resting-state neuroimaging: A review …
Girn et al. 2022: Serotonergic psychedelic drugs LSD and psilocybin reduce …
Schlag et al. 2022: Adverse effects of psychedelics: From anecdotes and misinf. …
Price et al. 2022: A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant …